Emerging therapies: Potential roles of SGLT2 inhibitors in the management of pulmonary hypertension
Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple clinical conditions and may be associated with a variety of cardiovascular and respiratory diseases. Pulmonary hypertension due to left heart disease (PH-LHD) currently lacks targeted therapies, while Pulmonary arterial hypertension (PAH), despite approved treatments, carries considerable residual risk. Metabolic dysfunction has been linked to the pathogenesis and prognosis of PH through various studies, with emerging metabolic agents offering a potential avenue for improving patient outcomes.
Source: Respiratory Medicine - Category: Respiratory Medicine Authors: Taimin Luo, Hui Wu, Wanlong Zhu, Liaoyun Zhang, Yilan Huang, Xuping Yang Source Type: research
More News: Cardiology | Cardiovascular | Heart | Heart Disease | Hypertension | Pulmonary Hypertension | Respiratory Medicine | SGLT2 Inhibitors | Study